We are live on
!
Find out more
ACM
ADAR1 Capital Management Portfolio holdings
AUM
$2.19B
Turnover
34.18%
1-Year Est. Return
374.99%
This Fund
S&P 500
This Quarter
Est. Return
+22.32%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
+$487M
(+29%)
Cap. Flow
+$166M
Cap. Flow
% of AUM
7.61%
Top 10 Holdings %
Top 10 Hldgs %
40.83%
Holding
354
New
43
Increased
102
Reduced
64
Closed
78
Avg Time Held Equity + Options
0.9
years
Top 10 Avg Time Held Equity + Options
1.1
years
Top 20 Avg Time Held Equity + Options
0.9
years
Avg Time Held Equity only
0.9
years
Top 10 Avg Time Held Equity only
1.3
years
Top 20 Avg Time Held Equity only
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abivax
ABVX
|
+$46.5M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$38.5M |
| 3 |
Zai Lab
ZLAB
|
+$38.4M |
| 4 |
Agios Pharmaceuticals
AGIO
|
+$34.8M |
| 5 |
Editas Medicine
EDIT
|
+$26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Terns Pharmaceuticals
TERN
|
+$48.2M |
| 2 |
Beam Therapeutics
BEAM
|
+$34.5M |
| 3 |
Scholar Rock
SRRK
|
+$20M |
| 4 |
Denali Therapeutics
DNLI
|
+$17.3M |
| 5 |
Cytokinetics
CYTK
|
+$12.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.67% |
| 2 | Miscellaneous | 11.02% |
| 3 | Financials | 2.15% |
| 4 | Real Estate | 0.05% |
| 5 | Communication Services | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
251
Milestone Pharmaceuticals
MIST
$98.1M
| $134K | 0.01% |
100,000
| – | – |
2025 Q4
2 quarters
|
|
252
Neuphoria Therapeutics
NEUP
$17.5M
| $131K | 0.01% |
30,000
| – | – |
2025 Q4
2 quarters
|
|
253
Neuronetics
STIM
$144M
| $130K | 0.01% |
100,000
| – | – |
2026 Q1
1 quarter
|
|
254
Chemomab Therapeutics
CMMB
$9.45M
| $130K | 0.01% |
80,000
| – | – |
2025 Q4
2 quarters
|
|
255
CALL
Solidion Technology
STI
$41.8M
| $125K | 0.01% |
13,500
| – | – |
2025 Q3
3 quarters
|
|
256
Voyager Therapeutics
VYGR
$124M
| $123K | 0.01% |
35,000
| – | – |
2023 Q4
10 quarters
|
|
257
Entrada Therapeutics
TRDA
$177M
| $114K | 0.01% |
15,500
-15,000
| -49% | -$144K |
2026 Q1
1 quarter
|
|
258
Veru
VERU
$36.3M
| $110K | 0.01% |
35,000
| – | – |
2025 Q4
2 quarters
|
|
|
CAES
259
Cantor Equity Partners VII
CAES
$319M
| $101K | ﹤0.01% |
+10,000
| New | +$101K |
2026 Q2
0 quarters
|
|
260
Clene
CLNN
$47M
| $92.3K | ﹤0.01% |
+15,000
| New | +$93.5K |
2026 Q2
0 quarters
|
|
261
VistaGen Therapeutics
VTGN
$9.17M
| $79.4K | ﹤0.01% |
351,141
-400,000
| -53% | -$241K |
2024 Q3
7 quarters
|
|
|
LGVN
262
Longeveron
LGVN
$5.52M
| $76.2K | ﹤0.01% |
10,841
-9,159
| -46% | -$79.3K |
2026 Q1
1 quarter
|
|
263
Biomea Fusion
BMEA
$60.5M
| $63.8K | ﹤0.01% |
43,420
| – | – |
2025 Q4
2 quarters
|
|
264
Lite Strategy Inc
LITS
$35.6M
| $62.1K | ﹤0.01% |
67,292
| – | – |
2025 Q3
3 quarters
|
|
265
Jasper Therapeutics
JSPR
$16.7M
| $58.9K | ﹤0.01% |
140,000
| – | – |
2025 Q4
2 quarters
|
|
266
Ardelyx
ARDX
$824M
| $56.1K | ﹤0.01% |
11,000
-12,900
| -54% | -$78.7K |
2026 Q1
1 quarter
|
|
267
Gossamer Bio
GOSS
$54.4M
| $35K | ﹤0.01% |
2,657
-937
| -26% | -$20.9K |
2023 Q4
10 quarters
|
|
268
aTyr Pharma
ATYR
$18M
| $30.2K | ﹤0.01% |
50,685
| – | – |
2025 Q3
3 quarters
|
|
269
A SPAC III Acquisition Corp Right
ASPCR
| $19.1K | ﹤0.01% |
215,000
| – | – |
2025 Q1
5 quarters
|
|
270
ProQR Therapeutics
PRQR
$207M
| $18.6K | ﹤0.01% |
10,000
| – | – |
2024 Q4
6 quarters
|
|
271
BEST SPAC I Acquisition Corp Rights
BSAAR
| $16.6K | ﹤0.01% |
+100,000
| New | +$15.8K |
2026 Q2
0 quarters
|
|
272
Coherus Oncology
CHRS
$162M
| $14.5K | ﹤0.01% |
10,366
| – | – |
2025 Q2
4 quarters
|
|
273
Adicet Bio
ACET
$45.8M
| – | – |
-53,827
| Closed | -$367K | – |
|
274
DELISTED
Arcellx
ACLX
| – | – |
-32,084
| Closed | -$3.68M | – |
|
275
Aclaris Therapeutics
ACRS
$498M
| – | – |
-132,426
| Closed | -$497K | – |
|
Similar funds
GAMH
RCAG
AF
AWM
TCM
WRBC
IAN
BOI
ADAR1 Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, ADAR1 Capital Management held 354 positions worth $2.19B, up 29% from $1.7B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
ADAR1 Capital Management deployed $166M of net new capital in Q2 2026, opening 43 new positions and adding to 102 existing holdings. Its largest new stake was Editas Medicine: 8,889,000 shares worth $28.8M.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Denali Therapeutics, an estimated $17.3M trimmed.
- ADAR1 Capital Management's largest Q2 2026 buy was Editas Medicine: 8,889,000 shares worth $28.8M.
- ADAR1 Capital Management added most to Abivax in Q2 2026, an estimated $46.5M increase.
- ADAR1 Capital Management's biggest Q2 2026 reduction was Denali Therapeutics, cutting an estimated $17.3M.
- ADAR1 Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $48.2M.
- ADAR1 Capital Management's ten largest holdings make up 41% of its $2.19B portfolio in Q2 2026.
- ADAR1 Capital Management opened 43 new positions and closed 78 in Q2 2026.
- ADAR1 Capital Management's portfolio value rose 29% quarter-over-quarter to $2.19B.
Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.